[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537820":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":90,"collaborators":10,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":10,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":10,"studyType":106,"phases":10,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"First Hospital of China Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Anthracycline-Based Breast Cancer Chemotherapy Group",null,"Age ≥18 years, histologically or cytopathologically confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy, with a prechemotherapy LVEF≥53%.",[13],"Device: Echocardiography",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Echocardiography","Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software",[9],[21],{"name":22,"affiliation":23,"role":24},"Yonghuai Wang, Ph.D","the First Hospital of China Medical Univeristy","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+86 15998323056","wyh_wyh2012@163.com",[31,47,59,67,78],{"facility":32,"status":33,"city":34,"state":35,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Fujian Cancer Hospital","RECRUITING","Fuzhou","Fujian","China","CN",{"type":39,"coordinates":40},"Point",[41,42],119.30611,26.06139,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":10,"phoneExt":10,"email":10},"Weiqin Huang",{"facility":48,"status":33,"city":49,"state":50,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Dalian Friendship Hospital","Dalian","Liaoning",{"type":39,"coordinates":52},[53,54],121.60222,38.91222,{"lat":54,"lon":53},[57],{"name":58,"role":27,"phone":10,"phoneExt":10,"email":10},"Bo Zhang",{"facility":60,"status":33,"city":49,"state":50,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Dalian Municipal Central Hospital",{"type":39,"coordinates":62},[53,54],{"lat":54,"lon":53},[65],{"name":66,"role":27,"phone":10,"phoneExt":10,"email":10},"Qingxiong Yue",{"facility":68,"status":33,"city":69,"state":50,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Liaoning Cancer Hospital & Institute","Shenyang",{"type":39,"coordinates":71},[72,73],123.43278,41.79222,{"lat":73,"lon":72},[76],{"name":77,"role":27,"phone":10,"phoneExt":10,"email":10},"Xiaoxue Zhang",{"facility":79,"status":33,"city":80,"state":81,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"The Third People's Hospital Of Chengdu","Chengdu","Sichuan",{"type":39,"coordinates":83},[84,85],104.06667,30.66667,{"lat":85,"lon":84},[88],{"name":89,"role":27,"phone":10,"phoneExt":10,"email":10},"Min Xu",{"type":24,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chunyan Ma","Chief of Cardiovascular Ultrasound","100537820","early-prediction-and-warning-for-cardiotoxicity-due-to-anthracycline-based-breast-cancer-chemotherapy-100537820",false,"NCT06282796","Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy","Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy: a Prospective, Multicenter, Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy\n* LVEF≥53% before chemotherapy\n\nExclusion Criteria:\n\n* life expectancy ≤12 months\n* Participating in other ongoing oncology clinical trials\n* Prior treatment with anthracyclines or chest radiation therapy\n* Pregnant or lactating women\n* Ultrasound images of the heart are of very poor quality","FEMALE","18 Years","80 Years",{"count":104,"type":105},600,"ESTIMATED","OBSERVATIONAL","This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.",[109],"Breast Cancer",[111,112,113,114],"Breast Cancer Chemotherapy","Anthracyclines","Cardiotoxicity","Early detection","2024-02-21",{"date":117,"type":118},"2024-02-28","ACTUAL",{"date":120,"type":118},"2024-01-01",{"date":122,"type":105},"2028-12-31",{"name":5,"class":6},5]